{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T22:33:13Z","timestamp":1768084393405,"version":"3.49.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PhD grant (SFRH\/BD\/123012\/2016)."],"award-info":[{"award-number":["PhD grant (SFRH\/BD\/123012\/2016)."]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metabolomics"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s11306-018-1384-2","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T08:06:40Z","timestamp":1529309200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["NMR-based metabolomics studies of human prostate cancer tissue"],"prefix":"10.1007","volume":"14","author":[{"given":"Ana Rita","family":"Lima","sequence":"first","affiliation":[]},{"given":"Joana","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Maria de Lourdes","family":"Bastos","sequence":"additional","affiliation":[]},{"given":"M\u00e1rcia","family":"Carvalho","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7395-5700","authenticated-orcid":false,"given":"Paula","family":"Guedes de Pinho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,6,18]]},"reference":[{"key":"1384_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.06.019","author":"AR Alberts","year":"2017","unstructured":"Alberts, A. R., Schoots, I. G., Bokhorst, L. P., Drost, F. H., van Leenders, G. J., Krestin, G. P., et al. (2017). Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can we selectively detect high-grade prostate cancer with upfront multivariable risk stratification and magnetic resonance imaging? European Urology. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2017.06.019\n                    \n                  .","journal-title":"European Urology"},{"key":"1384_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/501213","author":"F Aoun","year":"2014","unstructured":"Aoun, F., Peltier, A., & van Velthoven, R. (2014). A comprehensive review of contemporary role of local treatment of the primary tumor and\/or the metastases in metastatic prostate cancer. BioMed Research International. \n                    https:\/\/doi.org\/10.1155\/2014\/501213\n                    \n                  .","journal-title":"BioMed Research International"},{"issue":"13","key":"1384_CR3","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJMe0901166","volume":"360","author":"MJ Barry","year":"2009","unstructured":"Barry, M. J. (2009). Screening for prostate cancer: The controversy that refuses to die. The New England Journal of Medicine, 360(13), 1351\u20131354. \n                    https:\/\/doi.org\/10.1056\/NEJMe0901166\n                    \n                  .","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"1384_CR4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/nprot.2010.45","volume":"5","author":"O Beckonert","year":"2010","unstructured":"Beckonert, O., Coen, M., Keun, H. C., Wang, Y., Ebbels, T. M., Holmes, E., et al. (2010). High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nature Protocols, 5(6), 1019\u20131032. \n                    https:\/\/doi.org\/10.1038\/nprot.2010.45\n                    \n                  .","journal-title":"Nature Protocols"},{"issue":"11","key":"1384_CR5","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1038\/nprot.2007.376","volume":"2","author":"O Beckonert","year":"2007","unstructured":"Beckonert, O., Keun, H. C., Ebbels, T. M., Bundy, J., Holmes, E., Lindon, J. C., et al. (2007). Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nature Protocols, 2(11), 2692\u20132703. \n                    https:\/\/doi.org\/10.1038\/nprot.2007.376\n                    \n                  .","journal-title":"Nature Protocols"},{"issue":"11","key":"1384_CR6","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/bjc.2017.346","volume":"117","author":"PR Braadland","year":"2017","unstructured":"Braadland, P. R., Giskeodegard, G., Sandsmark, E., Bertilsson, H., Euceda, L. R., Hansen, A. F., et al. (2017). Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy. British Journal of Cancer, 117(11), 1656\u20131664. \n                    https:\/\/doi.org\/10.1038\/bjc.2017.346\n                    \n                  .","journal-title":"British Journal of Cancer"},{"issue":"15\u201316","key":"1384_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.drudis.2010.06.012","volume":"15","author":"M Cuperlovic-Culf","year":"2010","unstructured":"Cuperlovic-Culf, M., Barnett, D. A., Culf, A. S., & Chute, I. (2010). Cell culture metabolomics: Applications and future directions. Drug Discovery Today, 15(15\u201316), 610\u2013621. \n                    https:\/\/doi.org\/10.1016\/j.drudis.2010.06.012\n                    \n                  .","journal-title":"Drug Discovery Today"},{"issue":"1","key":"1384_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/nbm.2944","volume":"27","author":"EA Decelle","year":"2014","unstructured":"Decelle, E. A., & Cheng, L. L. (2014). High-resolution magic angle spinning 1H MRS in prostate cancer. NMR in Biomedicine, 27(1), 90\u201399. \n                    https:\/\/doi.org\/10.1002\/nbm.2944\n                    \n                  .","journal-title":"NMR in Biomedicine"},{"issue":"6","key":"1384_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrurol.2011.53","volume":"8","author":"EM DeFeo","year":"2011","unstructured":"DeFeo, E. M., Wu, C. L., McDougal, W. S., & Cheng, L. L. (2011). A decade in prostate cancer: From NMR to metabolomics. Nature Reviews Urology, 8(6), 301\u2013311. \n                    https:\/\/doi.org\/10.1038\/nrurol.2011.53\n                    \n                  .","journal-title":"Nature Reviews Urology"},{"key":"1384_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/890697","author":"A Dimakakos","year":"2014","unstructured":"Dimakakos, A., Armakolas, A., & Koutsilieris, M. (2014). Novel tools for prostate cancer prognosis, diagnosis, and follow-up. BioMed Research International. \n                    https:\/\/doi.org\/10.1155\/2014\/890697\n                    \n                  .","journal-title":"BioMed Research International"},{"issue":"3","key":"1384_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/pcan.2011.70","volume":"15","author":"R Dittrich","year":"2012","unstructured":"Dittrich, R., Kurth, J., Decelle, E. A., DeFeo, E. M., Taupitz, M., Wu, S., et al. (2012). Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy. Prostate Cancer and Prostatic Diseases, 15(3), 278\u2013282. \n                    https:\/\/doi.org\/10.1038\/pcan.2011.70\n                    \n                  .","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"6","key":"1384_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jprot.2009.01.007","volume":"72","author":"RR Drake","year":"2009","unstructured":"Drake, R. R., White, K. Y., Fuller, T. W., Igwe, E., Clements, M. A., Nyalwidhe, J. O., et al. (2009). Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. Journal of Proteomics, 72(6), 907\u2013917. \n                    https:\/\/doi.org\/10.1016\/j.jprot.2009.01.007\n                    \n                  .","journal-title":"Journal of Proteomics"},{"issue":"5","key":"1384_CR13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1039\/b418288j","volume":"130","author":"WB Dunn","year":"2005","unstructured":"Dunn, W. B., Bailey, N. J., & Johnson, H. E. (2005). Measuring the metabolome: Current analytical technologies. Analyst, 130(5), 606\u2013625. \n                    https:\/\/doi.org\/10.1039\/b418288j\n                    \n                  .","journal-title":"Analyst"},{"key":"1384_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.pnmrs.2009.07.003","volume":"55","author":"T Ebbels","year":"2009","unstructured":"Ebbels, T., & Cavill, R. (2009). Bioinformatic methods in NMR-based metabolic profiling. Progress in Nuclear Magnetic Resonance Spectroscopy, 55, 361\u2013374.","journal-title":"Progress in Nuclear Magnetic Resonance Spectroscopy"},{"key":"1384_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/metabo6010011","author":"TL Fuss","year":"2016","unstructured":"Fuss, T. L., & Cheng, L. L. (2016). Evaluation of cancer metabolomics using ex vivo high resolution magic angle spinning (HRMAS) magnetic resonance spectroscopy (MRS). Metabolites. \n                    https:\/\/doi.org\/10.3390\/metabo6010011\n                    \n                  .","journal-title":"Metabolites"},{"issue":"5","key":"1384_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00432-011-1134-6","volume":"138","author":"H Gao","year":"2012","unstructured":"Gao, H., Dong, B., Jia, J., Zhu, H., Diao, C., Yan, Z., et al. (2012). Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases. Journal of Cancer Research and Clinical Oncology, 138(5), 753\u2013761. \n                    https:\/\/doi.org\/10.1007\/s00432-011-1134-6\n                    \n                  .","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"4","key":"1384_CR17","doi-asserted-by":"publisher","first-page":"e62375","DOI":"10.1371\/journal.pone.0062375","volume":"8","author":"GF Giskeodegard","year":"2013","unstructured":"Giskeodegard, G. F., Bertilsson, H., Selnaes, K. M., Wright, A. J., Bathen, T. F., Viset, T., et al. (2013). Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLoS ONE, 8(4), e62375. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0062375\n                    \n                  .","journal-title":"PLoS ONE"},{"key":"1384_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.urology.2016.11.004","volume":"102","author":"E Gomez-Gomez","year":"2017","unstructured":"Gomez-Gomez, E., Carrasco-Valiente, J., Blanca-Pedregosa, A., Barco-Sanchez, B., Fernandez-Rueda, J. L., Molina-Abril, H., et al. (2017). European Randomized Study of Screening for Prostate Cancer Risk Calculator: External validation, variability, and clinical significance. Urology, 102, 85\u201391. \n                    https:\/\/doi.org\/10.1016\/j.urology.2016.11.004\n                    \n                  .","journal-title":"Urology"},{"issue":"27","key":"1384_CR19","doi-asserted-by":"publisher","first-page":"42071","DOI":"10.18632\/oncotarget.9817","volume":"7","author":"AF Hansen","year":"2016","unstructured":"Hansen, A. F., Sandsmark, E., Rye, M. B., Wright, A. J., Bertilsson, H., Richardsen, E., et al. (2016). Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer. Oncotarget, 7(27), 42071\u201342085. \n                    https:\/\/doi.org\/10.18632\/oncotarget.9817\n                    \n                  .","journal-title":"Oncotarget"},{"issue":"1","key":"1384_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., et al. (2014). EAU guidelines on prostate cancer part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. European Urology, 65(1), 124\u2013137. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2013.09.046\n                    \n                  .","journal-title":"European Urology"},{"issue":"6","key":"1384_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/nbm.1738","volume":"24","author":"KR Keshari","year":"2011","unstructured":"Keshari, K. R., Tsachres, H., Iman, R., Delos Santos, L., Tabatabai, Z. L., Shinohara, K., et al. (2011). Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage: Impact of tissue environment. NMR in Biomedicine, 24(6), 691\u2013699. \n                    https:\/\/doi.org\/10.1002\/nbm.1738\n                    \n                  .","journal-title":"NMR in Biomedicine"},{"issue":"4","key":"1384_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/mrm.22677","volume":"65","author":"RA Komoroski","year":"2011","unstructured":"Komoroski, R. A., Holder, J. C., Pappas, A. A., & Finkbeiner, A. E. (2011). 31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia. Magnetic Resonance in Medicine, 65(4), 911\u2013913. \n                    https:\/\/doi.org\/10.1002\/mrm.22677\n                    \n                  .","journal-title":"Magnetic Resonance in Medicine"},{"issue":"3","key":"1384_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1615\/CritRevBiomedEng.2013007736","volume":"41","author":"AK Kosmides","year":"2013","unstructured":"Kosmides, A. K., Kamisoglu, K., Calvano, S. E., Corbett, S. A., & Androulakis, I. P. (2013). Metabolomic fingerprinting: Challenges and opportunities. Critical Reviews in Biomedical Engineering, 41(3), 205\u2013221.","journal-title":"Critical Reviews in Biomedical Engineering"},{"issue":"6","key":"1384_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1586\/14737159.2016.1164037","volume":"16","author":"D Kumar","year":"2016","unstructured":"Kumar, D., Gupta, A., & Nath, K. (2016). NMR-based metabolomics of prostate cancer: A protagonist in clinical diagnostics. Expert Review of Molecular Diagnostics, 16(6), 651\u2013661. \n                    https:\/\/doi.org\/10.1586\/14737159.2016.1164037\n                    \n                  .","journal-title":"Expert Review of Molecular Diagnostics"},{"issue":"1","key":"1384_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/nbm.2979","volume":"27","author":"V Kumar","year":"2014","unstructured":"Kumar, V., Dwivedi, D. K., & Jagannathan, N. R. (2014). High-resolution NMR spectroscopy of human body fluids and tissues in relation to prostate cancer. NMR in Biomedicine, 27(1), 80\u201389. \n                    https:\/\/doi.org\/10.1002\/nbm.2979\n                    \n                  .","journal-title":"NMR in Biomedicine"},{"issue":"2 Pt 1","key":"1384_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/01.ju.0000074707.49775.46","volume":"170","author":"JS Lam","year":"2003","unstructured":"Lam, J. S., Cheung, Y. K., Benson, M. C., & Goluboff, E. T. (2003). Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic-American and white men. The Journal of Urology, 170(2 Pt 1), 451\u2013456. \n                    https:\/\/doi.org\/10.1097\/01.ju.0000074707.49775.46\n                    \n                  .","journal-title":"The Journal of Urology"},{"issue":"2","key":"1384_CR27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1021\/pr0605217","volume":"6","author":"EM Lenz","year":"2007","unstructured":"Lenz, E. M., & Wilson, I. D. (2007). Analytical strategies in metabonomics. Journal of Proteome Research, 6(2), 443\u2013458. \n                    https:\/\/doi.org\/10.1021\/pr0605217\n                    \n                  .","journal-title":"Journal of Proteome Research"},{"issue":"1","key":"1384_CR28","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1038\/s41598-018-23847-9","volume":"8","author":"AR Lima","year":"2018","unstructured":"Lima, A. R., Araujo, A. M., Pinto, J., Jeronimo, C., Henrique, R., Bastos, M. L., et al. (2018a). Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS. Scientific Reports, 8(1), 5539. \n                    https:\/\/doi.org\/10.1038\/s41598-018-23847-9\n                    \n                  .","journal-title":"Scientific Reports"},{"key":"1384_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/metabo8010023","author":"AR Lima","year":"2018","unstructured":"Lima, A. R., Araujo, A. M., Pinto, J., Jeronimo, C., Henrique, R., Bastos, M. L., et al. (2018b). GC-MS-based endometabolome analysis differentiates prostate cancer from normal prostate cells. Metabolites. \n                    https:\/\/doi.org\/10.3390\/metabo8010023\n                    \n                  .","journal-title":"Metabolites"},{"issue":"4","key":"1384_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.tranon.2016.05.004","volume":"9","author":"AR Lima","year":"2016","unstructured":"Lima, A. R., Mde, B., Carvalho, L., M., & Guedes de Pinho, P. (2016). Biomarker discovery in human prostate cancer: An update in metabolomics studies. Translational Oncology, 9(4), 357\u2013370. \n                    https:\/\/doi.org\/10.1016\/j.tranon.2016.05.004\n                    \n                  .","journal-title":"Translational Oncology"},{"issue":"1","key":"1384_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11306-006-0043-1","volume":"3","author":"CY Lin","year":"2007","unstructured":"Lin, C. Y., Wu, H., Tjeerdema, R. S., & Viant, M. R. (2007). Evaluation of metabolite extraction strategies from tissue samples using NMR metabolomics. Metabolomics, 3(1), 55\u201367. \n                    https:\/\/doi.org\/10.1007\/s11306-006-0043-1\n                    \n                  .","journal-title":"Metabolomics"},{"issue":"9","key":"1384_CR32","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1586\/14737159.2015.1069711","volume":"15","author":"G Lucarelli","year":"2015","unstructured":"Lucarelli, G., Rutigliano, M., Galleggiante, V., Giglio, A., Palazzo, S., Ferro, M., et al. (2015). Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. Expert Review of Molecular Diagnostics, 15(9), 1211\u20131224. \n                    https:\/\/doi.org\/10.1586\/14737159.2015.1069711\n                    \n                  .","journal-title":"Expert Review of Molecular Diagnostics"},{"key":"1384_CR33","first-page":"22","volume":"2014","author":"B Madhu","year":"2014","unstructured":"Madhu, B., Shaw, G. L., Warren, A. Y., Neal, D. E., & Griffiths, J. R. (2014). Absolute quantitation of metabolites in human prostate cancer biopsies by HR-MAS 1H NMR spectroscopy. Proceedings of the International Society for Magnetic Resonance in Medicine, 2014, 22.","journal-title":"Proceedings of the International Society for Magnetic Resonance in Medicine"},{"key":"1384_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11306-016-1055-0","volume":"12","author":"B Madhu","year":"2016","unstructured":"Madhu, B., Shaw, G. L., Warren, A. Y., Neal, D. E., & Griffiths, J. R. (2016). Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy. Metabolomics, 12, 120. \n                    https:\/\/doi.org\/10.1007\/s11306-016-1055-0\n                    \n                  .","journal-title":"Metabolomics"},{"key":"1384_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.copbio.2016.08.001","volume":"43","author":"JL Markley","year":"2017","unstructured":"Markley, J. L., Bruschweiler, R., Edison, A. S., Eghbalnia, H. R., Powers, R., Raftery, D., et al. (2017). The future of NMR-based metabolomics. Current Opinion in Biotechnology, 43, 34\u201340. \n                    https:\/\/doi.org\/10.1016\/j.copbio.2016.08.001\n                    \n                  .","journal-title":"Current Opinion in Biotechnology"},{"issue":"7","key":"1384_CR36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/pros.21103","volume":"70","author":"A Maxeiner","year":"2010","unstructured":"Maxeiner, A., Adkins, C. B., Zhang, Y., Taupitz, M., Halpern, E. F., McDougal, W. S., et al. (2010). Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate, 70(7), 710\u2013717. \n                    https:\/\/doi.org\/10.1002\/pros.21103\n                    \n                  .","journal-title":"Prostate"},{"issue":"14","key":"1384_CR37","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/pros.22704","volume":"73","author":"JE McDunn","year":"2013","unstructured":"McDunn, J. E., Li, Z., Adam, K. P., Neri, B. P., Wolfert, R. L., Milburn, M. V., et al. (2013). Metabolomic signatures of aggressive prostate cancer. Prostate, 73(14), 1547\u20131560. \n                    https:\/\/doi.org\/10.1002\/pros.22704\n                    \n                  .","journal-title":"Prostate"},{"issue":"1","key":"1384_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/1756287214555336","volume":"7","author":"AS Merseburger","year":"2015","unstructured":"Merseburger, A. S., Haas, G. P., & von Klot, C. A. (2015). An update on enzalutamide in the treatment of prostate cancer. Therapeutic Advances in Urology, 7(1), 9\u201321. \n                    https:\/\/doi.org\/10.1177\/1756287214555336\n                    \n                  .","journal-title":"Therapeutic Advances in Urology"},{"issue":"1","key":"1384_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/156802611793611869","volume":"11","author":"S Moestue","year":"2011","unstructured":"Moestue, S., Sitter, B., Bathen, T. F., Tessem, M. B., & Gribbestad, I. S. (2011). HR MAS MR spectroscopy in metabolic characterization of cancer. Current Topics in Medicinal Chemistry, 11(1), 2\u201326.","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"2","key":"1384_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2174\/092986713804806621","volume":"20","author":"M Monteiro","year":"2013","unstructured":"Monteiro, M., Carvalho, M., Bastos, M. L., & de Pinho, P. G. (2013). Metabolomics analysis for biomarker discovery: Advances and challenges. Current Medicinal Chemistry, 20(2), 257\u2013271.","journal-title":"Current Medicinal Chemistry"},{"issue":"2","key":"1384_CR41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","volume":"157","author":"VA Moyer","year":"2012","unstructured":"Moyer, V. A., & Force, U. S. P. S. T. (2012). Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 157(2), 120\u2013134. \n                    https:\/\/doi.org\/10.7326\/0003-4819-157-2-201207170-00459\n                    \n                  .","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"1384_CR42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4111\/kju.2011.52.2.79","volume":"52","author":"MJ Roberts","year":"2011","unstructured":"Roberts, M. J., Schirra, H. J., Lavin, M. F., & Gardiner, R. A. (2011). Metabolomics: A novel approach to early and noninvasive prostate cancer detection. Korean Journal of Urology, 52(2), 79\u201389. \n                    https:\/\/doi.org\/10.4111\/kju.2011.52.2.79\n                    \n                  .","journal-title":"Korean Journal of Urology"},{"issue":"8","key":"1384_CR43","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1600-0463.2009.02517.x","volume":"117","author":"K Rostad","year":"2009","unstructured":"Rostad, K., Hellwinkel, O. J., Haukaas, S. A., Halvorsen, O. J., Oyan, A. M., Haese, A., et al. (2009). TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS, 117(8), 575\u2013582. \n                    https:\/\/doi.org\/10.1111\/j.1600-0463.2009.02517.x\n                    \n                  .","journal-title":"APMIS"},{"issue":"4","key":"1384_CR44","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/nbm.1474","volume":"23","author":"CF Santos","year":"2010","unstructured":"Santos, C. F., Kurhanewicz, J., Tabatabai, Z. L., Simko, J. P., Keshari, K. R., Gbegnon, A., et al. (2010). Metabolic, pathologic, and genetic analysis of prostate tissues: Quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR in Biomedicine, 23(4), 391\u2013398. \n                    https:\/\/doi.org\/10.1002\/nbm.1474\n                    \n                  .","journal-title":"NMR in Biomedicine"},{"issue":"6","key":"1384_CR45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1756287214545328","volume":"6","author":"J Schalken","year":"2014","unstructured":"Schalken, J., Dijkstra, S., Baskin-Bey, E., & van Oort, I. (2014). Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer. Therapeutic Advances in Urology, 6(6), 245\u2013252. \n                    https:\/\/doi.org\/10.1177\/1756287214545328\n                    \n                  .","journal-title":"Therapeutic Advances in Urology"},{"issue":"1","key":"1384_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer Statistics 2017. CA: A Cancer Journal for Clinicians, 67(1), 7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21387\n                    \n                  .","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"2","key":"1384_CR47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1158\/1078-0432.CCR-08-1059","volume":"15","author":"JL Spratlin","year":"2009","unstructured":"Spratlin, J. L., Serkova, N. J., & Eckhardt, S. G. (2009). Clinical applications of metabolomics in oncology: A review. Clinical Cancer Research, 15(2), 431\u2013440. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1059\n                    \n                  .","journal-title":"Clinical Cancer Research"},{"issue":"Suppl 1","key":"1384_CR48","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1007\/s00259-013-2379-x","volume":"40","author":"EM Spur","year":"2013","unstructured":"Spur, E. M., Decelle, E. A., & Cheng, L. L. (2013). Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry. European Journal of Nuclear Medicine and Molecular Imaging, 40(Suppl 1), S60\u2013S71. \n                    https:\/\/doi.org\/10.1007\/s00259-013-2379-x\n                    \n                  .","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"7231","key":"1384_CR49","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/nature07762","volume":"457","author":"A Sreekumar","year":"2009","unstructured":"Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 457(7231), 910\u2013914. \n                    https:\/\/doi.org\/10.1038\/nature07762\n                    \n                  .","journal-title":"Nature"},{"issue":"6","key":"1384_CR50","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10334-009-0187-x","volume":"22","author":"K Stenman","year":"2009","unstructured":"Stenman, K., Hauksson, J. B., Grobner, G., Stattin, P., Bergh, A., & Riklund, K. (2009). Detection of polyunsaturated omega-6 fatty acid in human malignant prostate tissue by 1D and 2D high-resolution magic angle spinning NMR spectroscopy. MAGMA, 22(6), 327\u2013331. \n                    https:\/\/doi.org\/10.1007\/s10334-009-0187-x\n                    \n                  .","journal-title":"MAGMA"},{"key":"1384_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4137\/BMI.S6794","volume":"6","author":"K Stenman","year":"2011","unstructured":"Stenman, K., Stattin, P., Stenlund, H., Riklund, K., Grobner, G., & Bergh, A. (2011). H HRMAS NMR derived bio-markers related to tumor grade, tumor cell fraction, and cell proliferation in prostate tissue samples. Biomark Insights, 6, 39\u201347. \n                    https:\/\/doi.org\/10.4137\/BMI.S6794\n                    \n                  .","journal-title":"Biomark Insights"},{"issue":"1","key":"1384_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/mrm.21647","volume":"60","author":"MG Swanson","year":"2008","unstructured":"Swanson, M. G., Keshari, K. R., Tabatabai, Z. L., Simko, J. P., Shinohara, K., Carroll, P. R., et al. (2008). Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magnetic Resonance in Medicine, 60(1), 33\u201340. \n                    https:\/\/doi.org\/10.1002\/mrm.21647\n                    \n                  .","journal-title":"Magnetic Resonance in Medicine"},{"issue":"3","key":"1384_CR54","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mrm.21694","volume":"60","author":"MB Tessem","year":"2008","unstructured":"Tessem, M. B., Swanson, M. G., Keshari, K. R., Albers, M. J., Joun, D., Tabatabai, Z. L., et al. (2008). Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magnetic Resonance in Medicine, 60(3), 510\u2013516. \n                    https:\/\/doi.org\/10.1002\/mrm.21694\n                    \n                  .","journal-title":"Magnetic Resonance in Medicine"},{"issue":"5","key":"1384_CR55","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.urolonc.2011.08.002","volume":"29","author":"BJ Trock","year":"2011","unstructured":"Trock, B. J. (2011). Application of metabolomics to prostate cancer. Urologic Oncology, 29(5), 572\u2013581. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2011.08.002\n                    \n                  .","journal-title":"Urologic Oncology"},{"issue":"6","key":"1384_CR56","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10334-008-0156-9","volume":"21","author":"JJ Asten van","year":"2008","unstructured":"van Asten, J. J., Cuijpers, V., Hulsbergen-van de Kaa, C., Soede-Huijbregts, C., Witjes, J. A., Verhofstad, A., et al. (2008). High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. MAGMA, 21(6), 435\u2013442. \n                    https:\/\/doi.org\/10.1007\/s10334-008-0156-9\n                    \n                  .","journal-title":"MAGMA"},{"issue":"1","key":"1384_CR57","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1038\/s41598-018-23177-w","volume":"8","author":"LA Vandergrift","year":"2018","unstructured":"Vandergrift, L. A., Decelle, E. A., Kurth, J., Wu, S., Fuss, T. L., DeFeo, E. M., et al. (2018). Metabolomic prediction of human prostate cancer aggressiveness: Magnetic resonance spectroscopy of histologically benign tissue. Scientific Reports, 8(1), 4997. \n                    https:\/\/doi.org\/10.1038\/s41598-018-23177-w\n                    \n                  .","journal-title":"Scientific Reports"},{"issue":"9","key":"1384_CR58","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jnci\/djq099","volume":"102","author":"HG Welch","year":"2010","unstructured":"Welch, H. G., & Black, W. C. (2010). Overdiagnosis in cancer. Journal of the National Cancer Institute, 102(9), 605\u2013613. \n                    https:\/\/doi.org\/10.1093\/jnci\/djq099\n                    \n                  .","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"1384_CR59","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1586\/erm.09.73","volume":"10","author":"SY Yang","year":"2010","unstructured":"Yang, S. Y., Adelstein, J., & Kassis, A. I. (2010). Putative molecular signatures for the imaging of prostate cancer. Expert Review of Molecular Diagnostics, 10(1), 65\u201374. \n                    https:\/\/doi.org\/10.1586\/erm.09.73\n                    \n                  .","journal-title":"Expert Review of Molecular Diagnostics"},{"issue":"1","key":"1384_CR60","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12010-014-0955-6","volume":"174","author":"A Zhang","year":"2014","unstructured":"Zhang, A., Yan, G., Han, Y., & Wang, X. (2014). Metabolomics approaches and applications in prostate cancer research. Applied Biochemistry and Biotechnology, 174(1), 6\u201312. \n                    https:\/\/doi.org\/10.1007\/s12010-014-0955-6\n                    \n                  .","journal-title":"Applied Biochemistry and Biotechnology"}],"container-title":["Metabolomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11306-018-1384-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-018-1384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-018-1384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T19:25:25Z","timestamp":1560799525000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11306-018-1384-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,18]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1007\/s11306-018-1384-2","relation":{},"ISSN":["1573-3882","1573-3890"],"issn-type":[{"value":"1573-3882","type":"print"},{"value":"1573-3890","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,18]]},"assertion":[{"value":"3 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have read the journal\u2019s policy on disclosure of potential conflicts of interest and have none to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"88"}}